Advanced in Chronic Erosive Gastritis

P H. Liu-Peng

No. 61, West Jiefang Road, 
Changsha, CN 
Advanced in Chronic Erosive Gastritis
No. 61, West Jiefang Road, 
Changsha, CN 
OverviewLocationsClinical Research

Overview

P Liu-Peng practices in Changsha, China. Liu-Peng is rated as an Advanced expert by MediFind in the treatment of Chronic Erosive Gastritis. Their top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Brain Aneurysm, B-Cell Lymphoma, Spinal Fusion, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 3760 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Chronic Erosive Gastritis.

Locations

No. 61, West Jiefang Road, Changsha, 410002, China
Other Locations
180 Fenglin Road, Zhongshan, China
No. 139 Ziqiang Road, Shijiazhuang, 050051, China
49 Huayuan North Road, Huayuan, 100191, China
128 Xiangshan North Road, Nanchang, 330008, China
96 Jinzhai Road, Hefei, 230026, China
130 Dong An Road, Shanghai, 200032, China
1108 Gengwen Road, Hangzhou, 311231, China
37 Xueyuan Road, Haidian, 100191, China
16766 Jingshi Road, Jinan, 250014, China
No.28 Fuxing Road, Haidian, 100853, China
No. 87 Xiangya Road, Changsha, 410008, China
First Ring Road, Chengdu, 610072, China
61 Jiefang West Road, Changsha, China
72 Guangzhou Road, Nanjing, 210008, China
100 Haining Road, Shanghai, 200086, China
19B Yuquan Road, Yuquan, 100049, China
No. 628 Zhenyuan Road, Shenzhen, 518107, China
Baojian Road 157, Harbin, 150081, China
168 Changhai Road, Yangpu, China
Tongzipo Road 138, Changsha, 410013, China
899 Pinghai Road, Suzhou, 215006, China
No. 800, Dongchuan Road, Shanghai, 200240, China
China Japan Union Hospital of Jilin University
Changchun, 130031, China
100 Kexue Avenue, Zhengzhou, 450001, China
22 Shaoshan Road, Changsha, 410075, China
758 Hefei Road, Qingdao, 266035, China
Xueyuan Road 1098, Shenzhen, 518055, China
No. 35, Qinghua East Road, Beijing, 100083, China
No. 197 Ruijin 2nd Rd, Shanghai, 200025, China
382 East Outer Loop Road, University Park, Guangzhou, 510006, China
651 East Dong Feng Road, Guangzhou, 510060, China
103 Wenhua Road, Shenyang, 110016, China
No. 76 Nanguo Road, Xi'an, 710054, China
88 Jiefang Road, Hangzhou, 310009, China
No. 103, Wenhua Road, Shenyang, 110016, China
No. 256 Youyi Rd, Xi'an, 710068, China
35 Qinghua East Road, Beijing, 100083, China
No. 287 Renmin Road, Qingdao, 266400, China
No. 277 West Yan Ta Road, Xi'an, 710061, China
111 Guangzhou Liuhua Road, Guangzhou, 510010, China
107 West Wenhua Road, Jinan, China
Fujin Road, Changchun, 130021, China
No. 1098, Xueyuan Avenue, Shenzhen, 518055, China
109 Xueyuan W Road, Wenzhou, 325000, China
168 Changhai Road, Shanghai, 200433, China
No. 3 Yingrui Road, Jiangyin, China
965 XinJiang Road, Changchun, 130021, China
No. 22 Shuangyong Road, Nanning, 530021, China
Fudan University 180 Fenglin Road, Zhongshan, 200032, China
Zhongshan Road 222, Dalian, 116011, China
No. 222 Zhongshan Road, Dalian, 116021, China
43 People's Avenue, Haikou, 570028, China
19B Yuquan Road, Shijingshan, 100049, China
483 Wushan Road, Guangzhou, 510642, China
No. 132, East Waihuan Rd, Guangzhou, 510006, China
No. 76 Nanguo Road, Xi'an, China
No. 605 Lushan South Road, Changsha, 410012, China
222 Jianguo Road, Qinhuangdao, China
No.201 Hubin South Road, Xiamen, 361004, China
627 Wuluo Road, Wuhan, 430070, China
19B Yuquan Road, Shijingshan, China
No. 256 Youyi Road, Xi'an, 710068, China
Union Hospital, Wuhan, 430022, China
College Of Forest, No. 61, Daizong Street, Taian, 271018, China
1 College Of Light Industry And Food Sciences, Guangzhou, China
Changle West Road 169, Xi'an, 710032, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2025
Intervention Type: Combination product
Study Drugs: Selinexor+Bortezomib+Dexamethasone, Bortezomib+Dexamethasone
Study Phase: Phase 3
Randomized Trial of Sorafenib Plus Hepatic Arterial Infusion with Oxaliplatin and Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis
Randomized Trial of Sorafenib Plus Hepatic Arterial Infusion with Oxaliplatin and Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug, Procedure
Study Phase: Phase 2
A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: April 30, 2024
Intervention Type: Combination product, Drug
Study Drugs: ATG-019 PAK4/NAMPT Dual Inhibitor, Niacin
Study Phase: Phase 1
Chindamide in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma, a Phase II Trial
Chindamide in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma, a Phase II Trial
Enrollment Status: Unknown
Publish Date: July 30, 2018
Intervention Type: Drug
Study Drugs: Chidamide, Lenalidomide, Dexamethasone
Study Phase: Phase 2
View 4 Less Clinical Trials

3754 Total Publications

Multi-omics insights into gut microbial dysbiosis and metabolic alterations in immune checkpoint inhibitor-induced thrombocytopenia.
Multi-omics insights into gut microbial dysbiosis and metabolic alterations in immune checkpoint inhibitor-induced thrombocytopenia.
Journal: Immunotherapy
Published: January 23, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu-Peng's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 118 Advanced Conditions
    View All 290 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile